hydrochlorothiazide has been researched along with abiraterone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bedussi, F; Berruti, A; Dalla Volta, A; Ferrari, V; Fragni, M; Galli, D; Lazzari, B; Memo, M; Roca, E; Rossini, E; Sigala, S; Valcamonico, F; Vezzoli, S | 1 |
2 other study(ies) available for hydrochlorothiazide and abiraterone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.
Topics: Amiloride; Androgens; Androstenes; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Humans; Hydrochlorothiazide; Male; Mineralocorticoid Excess Syndrome, Apparent; Mineralocorticoids; Prostatic Neoplasms | 2017 |